摘要： 中国上海·美国纽约 2025年6月10日，三优生物医药（上海）有限公司（以下简称“三优生物”）宣布与美国Medicovestor, Inc.（以下简称“Medicovestor”）签订战略合作协议，共同推进新一代First in class化疗免疫抗体偶联
中国上海·美国纽约 2025年6月10日，三优生物医药（上海）有限公司（以下简称“三优生物”）宣布与美国Medicovestor, Inc.（以下简称“Medicovestor”）签订战略合作协议，共同推进新一代First in class化疗免疫抗体偶联药物（“化疗免疫”型ADC）的开发。
▲ Medicovestor 与三优生物签订战略合作协议
Medicovester COO Lin Ong，白帆总经理谭凯、商务负责人罗武松，三优研发副总裁郑海亮、外联部经理陈美玲共同见证
该合作协议已于2025年6月6日正式签署。双方将结合三优生物全球领先的智能超万亿分子库（AI-STAL）技术和智能化药物筛选与临床前研究，以及Medicovestor专有的ADC平台技术——包括创新型二聚抗体结构平台ADoBindTM与双表位靶向系统ADoTopeTM，致力于加速开发用于肿瘤和自身免疫性疾病治疗的新一代化疗免疫抗体偶联药物。
Medicovestor是一家美国生物技术公司，致力于开发新一代化疗免疫ADC，用于治疗癌症和自身免疫性疾病。公司拥有两大专有技术平台，能以更低剂量实现更高疗效，并支持联合疗法。其主导项目已进入IND-enabling阶段，其中针对胰腺癌的疗法已提交FDA Orphan Drug Designation申请。公司目前持有11项授权专利和3项待批专利，在ADC领域具有独特优势。
Medicovestor创始人Seah Lim博士深耕生物医药领域25年，是全球顶尖的转化医学科学家。在学术界，Seah博士曾担任英国和美国多所大学（包括布朗大学和匹兹堡大学医学院等）的全职教授，并多次担任领导职务（科主任等）；在工业界，Seah博士曾担任Bausch Health、Genzyme和Burroughs Wellcome & Company等公司的产品研发顾问，并曾任赛诺菲（Sanofi）公司全球项目的儿科负责人以及独立董事和Genie Therapeutics, Inc.的商业与科学顾问。Seah博士不仅具备深厚的科学和行业背景，还拥有丰富的临床实践经验。
▲ Medicovestor CEO Seah Lim博士和三优生物CEO郎国竣博士
Medicovestor创始人兼CEO Seah Lim博士表示：“此次合作体现了我们对ADC重新定义的承诺——通过将我们差异化的平台与三优生物在抗体开发方面的世界级专业技术相融合，实现在ADC中整合免疫治疗的创新理念。双方的互补优势将共同推动突破性疗法的开发，为治疗选择有限的患者带来新希望！”
三优生物创始人兼CEO郎国竣博士表示：“我们非常高兴能与Medicovestor开展合作，推动其高度创新的化疗免疫ADC走向临床。通过紧密协同技术互补，我们希望共同打造改变患者生活的变革性疗法惠及全球患者！”
本次战略合作内容包括联合研究、技术转移与领先候选药物的共同开发。双方计划在未来几个季度公布项目进展与候选药物筛选结果。
关于Medicovestor
Medicovestor是一家总部位于美国纽约的生物技术公司，专注于开发用于肿瘤和自身免疫性疾病治疗的化疗免疫抗体偶联药物（ADC）。公司的两项专有平台技术——ADoBind（创新型二聚抗体结构）和ADoTope（双效载药靶向技术）旨在提升肿瘤选择性并降低系统性毒性，从而释放出超越传统ADC应用的新治疗潜力。
关于三优生物
三优生物是一家以“运用创新生物药提高人类的生活品质”为愿景，以“让天下没有难做的创新生物药”为使命的生物医药高新技术企业。公司总部位于中国上海，在美国、欧洲等地设有子公司，现有投产及布局的研发及GMP场地20000多平方米。
公司以智能超万亿分子库为核心，打造了国际领先的创新生物药临床前智能化及一体化研发平台，通过“新药发现、临床前研究、智能化药物研发及前沿科学研究”等四个维度加速创新生物药物的研发进程。
公司为合作伙伴提供“差异化CRO、整合型CDO、协同型CPO、特色CRS”于一体的“创新生物药4C综合业务”。公司已建立全球营销网络，已与全球1200多家药企、生技公司等建立了良好的合作关系；已完成了1200多个新药发现及开发服务项目；已完成了50多个合作研发项目，其中9个合作项目已完成临床申报；公司开发了数千种品牌试剂。
公司已获得国家高新技术、上海市专精特新、上海市小巨人和上海“张江之星”企业认定。
Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
Shanghai, China & New York, USA — June 10, 2025 — Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D today announced the signing of a strategic cooperation agreement with Medicovestor, Inc., a New York-based biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs).
▲ Medicovestor and Sanyou Biopharmaceuticals signed a strategic partnership agreement, witnessed by Medicovestor COO Lin Ong; Dragon sail pharmaceutical General Manager Kai Tan and Business Director Wusong Luo; Sanyou Biopharmaceuticals Vice President of R&D Hailiang Zheng; and Outreach Manager Meiling Chen.
The agreement, officially signed on June 6, brings together Medicovestor’s proprietary ADC platforms—ADoBind, a novel dimeric antibody architecture, and ADoTope, a bi-epitope targeting system—with Sanyou’s globally leading AI-STAL (Artificial Intelligence-enabled Super Trillion Antibody Library) technology and intelligent drug screening and preclinical research capabilities. The collaboration aims to accelerate the development of first-in-class chemoimmunotherapies for oncology and autoimmune diseases so that it is “chemoimmunotherapy” ADCs.
Medicovestor is a U.S.-based biotechnology company dedicated to developing next-generation chemoimmunotherapies antibody-drug conjugates (ADCs) for the treatment of cancer and autoimmune diseases. The company has two proprietary technology platforms that enable higher efficacy at lower doses and support combination therapies. Its lead program has entered the IND-enabling stage, with a pancreatic cancer therapy submitted for FDA Orphan Drug Designation. Medicovestor currently holds 11 granted patents and 3 pending applications, positioning the company with a distinct competitive edge in the ADC field.
Dr. Seah Lim, Founder of Medicovestor, has over 25 years of experience in the biopharmaceutical industry and is recognized as a leading global expert in translational medicine. In academia, Dr. Lim has served as a full professor at several prestigious universities in the United Kingdom and the United States, including Brown University and the University of Pittsburgh School of Medicine, where he held multiple leadership positions such as Division Chief. In industry, he has worked as a Product Development Consultant for companies including Bausch Health, Genzyme, and Burroughs Wellcome & Company. He also served as the Pediatric Lead in the Global Program at Sanofi and has held advisory roles such as Independent Director and Commercial & Scientific Advisor at Genie Therapeutics, Inc. Dr. Seah Lim brings not only deep scientific and industry expertise but also extensive clinical experience to the company.
▲ Dr. Seah Lim, CEO of Medicovestor, and Dr. Guojun Lang, CEO of Sanyou Biopharmaceuticals
“This partnership reflects our commitment to redefining ADCs by integrating our differentiated ADC platforms with Sanyou’s world-class expertise in antibody development to incorporate immunotherapy into ADCs,” said Seah Lim, MD, PhD, Founder and CEO of Medicovestor. “Together, our complementary strengths create a powerful engine to unlock novel therapeutic possibilities for patients with limited treatment options.”
“We are excited to collaborate with Medicovestor to realize the promise of their highly innovative chemoimmunotherapy ADC platforms,” said David Lang, PhD, Founder and CEO of Sanyou Biopharmaceuticals. “By combining scientific excellence with execution capability, we aim to deliver transformative therapies that change patients’ lives.”
The partnership includes joint research, technology transfer, and co-development of lead candidates. Both companies plan to announce development milestones and candidate selections in the coming quarters.
About Medicovestor, Inc.
Medicovestor is a biotechnology company headquartered in New York City, focused on advancing chemoimmunotherapy antibody-drug conjugates (ADCs) for oncology and autoimmune diseases. The company’s proprietary platforms—ADoBind, a novel dimeric antibody structure, and ADoTope, a dual-payload targeting technology—are designed to enhance tumor selectivity and minimize systemic toxicity, unlocking new therapeutic potential beyond conventional ADC applications.
About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals Co., Ltd. is a high-tech biopharmaceutical company with the vision of "improving the quality of human life through innovative biologics" and the mission of " to make the R&D easy for innovative biologics". The company is headquartered in Shanghai, China, with subsidiaries in the United States, Europe, and other regions. It has over 20,000 square meters of R&D and GMP facilities that are currently in operation or under planning.
The company has established a world-leading preclinical intelligent and integrated R&D platform for innovative biologics, centered around an innovative platform of super-trillion antibody library. This platform accelerates the development of innovative biologics across four dimensions: new drug discovery, preclinical research, AI-assisted drug development, and frontier scientific research.
Sanyou provides a comprehensive "4C" business model for innovative biologics, combining differentiated CRO, integrated CDO, collaborative CPO, and specialized CRS. The company has built a global marketing network and established business with over 1,200 pharmaceutical and biotech companies worldwide. It has completed more than 1,200 new drug discovery and development service projects, with over 50 collaborative R&D projects, including 9 that have obtained IND approval. The company has also developed thousands of RUO reagents. Sanyou has also received a number of nationwide and Shanghai recognitions and awards.
来源：快分享
